Stock VIRO VIROGATES A/S
Add to a list
To use this feature you must be a member
Log inSign up

News ViroGates A/S

Equities

VIRO

DK0061030574

Delayed Nasdaq Copenhagen
Other stock markets
 03:51:58 2024-04-24 am EDT 		5-day change 1st Jan Change
6.88 DKK +6.17% Intraday chart for ViroGates A/S +9.90% +14.29%
Apr. 15 Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration CI
Mar. 21 ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ViroGates announces the outcome of its Q-Submission filing for suPARnostic® TurbiLatex with the US FDA and the overall timeline for filing a submission of a 510k/“De Novo” application with the FDA
AQ
Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration
CI
ViroGates gives notice to convene the Annual General Meeting on 25 April 2024
AQ
ViroGates announces its Annual Report 2023: Revenue was affected by the loss of COVID-19 customers and a difficult transition into general triage
AQ
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Subscription of shares by majority shareholder in relation to the recently completed rights emission in ViroGates A/S
AQ
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
AQ
ViroGates publishes its financial calendar for 2024
AQ
ViroGates announces financial guidance for 2024
AQ
ViroGates A/S Provides Earnings Guidance for the Year 2024
CI
ViroGates' capital raise of DKK 13.9 million and issue of 3,097,047 new shares have been registered
AQ
ViroGates announces the outcome of its rights issue
AQ
ViroGates A/S : Most interesting suPAR studies of 2023
PU
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
AQ
ViroGates A/S : Clinical role of suPAR in the prognosis of patients in the emergency setting and its influence on risk stratification
PU
The subscription period in ViroGates’ rights issue begins today
AQ
Resolutions from the Extraordinary General Meeting of ViroGates A/S
AQ
ViroGates A/S : Social isolation in mid-adulthood is associated with elevated suPAR
PU
ViroGates gives notice to convene an Extraordinary General Meeting on 24 November 2023
AQ
ViroGates announces an offering of new shares with pre-emptive rights for existing shareholders
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VIRO Stock
  4. News ViroGates A/S